The new president and CEO of NPR worked for nearly two decades in broadcast radio. But he says it’s his recent experience as a business executive and investor that will strengthen the 45-year-old media organization. A conversation with Jarl Mohn about the future of public radio.
An FDA advisory board recommended withdrawing government approval for the breast cancer drug, Avastin. Pros and cons of the decision and its implications for FDA’s accelerated approval process to treat serious and life threatening diseases.
- Dr. Peter Bach attending physician and director of the Center for Health Policy and Outcomes at Memorial Sloan-Kettering Cancer Center, and a former adviser to Medicare.
- Dr. Carolyn Hendricks a medical oncologist affiliated with Suburban Hospital in Bethesda.
- William Hubbard former associate commissioner for the Food and Drug Administration; spokesperson for the Alliance for a Stronger FDA
- Gardiner Harris science reporter for "The New York Times" and author of the mystery novel 'Hazard.'
Most Recent Shows
A Justice Department investigation finds a pattern of racial discrimination by police officers and courts in Ferguson, Missouri. Diane and guests discuss what's in the new report and how it could affect police departments nationwide.
We live in an age when science and technology touch nearly every aspect of our lives. Yet scientific findings on climate change, vaccines and evolution are increasingly under attack. Why people doubt science.
On Tuesday, Israeli Prime Minister Benjamin Netanyahu delivered a much-debated speech to Congress. We look at reaction to the speech here and abroad and efforts to reduce U.S.-Israeli tensions over a possible nuclear agreement with Iran.